To The Moon

$Aligos Therapeutics, Inc.(ALGS)$ $Gilead Sciences(GILD)$ $Arbutus Biopharma(ABUS)$ 🧪 Clinical conviction with ALG-000184

I’m fully convinced $ALGS (Aligos Therapeutics) is one of the most misunderstood small-cap biotech setups in the market. I’ve held this position for a long time because of my personal conviction in their science and its potential impact on someone I care about who struggles with liver disease.

I’m confident Phase 2 B-SUPREME is the core catalyst. With regulatory approvals across multiple countries, ~200 patients enrolled, and Phase 1 data showing significant HBV DNA reductions after 96 weeks, this program has durability and credibility. It’s not speculative noise; it’s execution in motion.

💵 Balance sheet discipline, cash runway intact

I’m watching the financials closely. Q2 2025 saw a net loss of $15.9M versus a $5.1M profit last year, but Aligos still carries $122.9M in cash and investments; enough to fund operations into 2026. R&D spend dropped to $14M, signaling discipline even as trials advance. That balance of burn control and clinical progress is critical at this stage.

📈 Analysts price in exponential upside

I’m encouraged by HC Wainwright’s new Buy rating with a $50 PT, announced this week. Across four analysts, the average target sits at $85.25 with a high of $175. From today’s ~$9 handle, that’s 858% to 1,254% upside. These are not fantasy projections; they’re anchored in the potential of ALG-000184 to become a first-line HBV therapy.

📊 Analyst consensus signals conviction

I’m here for the sentiment shift. Four analysts now cover $ALGS: 25% rate it Strong Buy, 75% Buy, with 0% Hold or Sell. That’s rare unanimity in biotech coverage, especially for a sub-$60M market cap. When consensus tilts this hard, it tells me conviction is rising even as the market remains skeptical.

🔍 Short positioning as latent fuel

I’m tracking short data carefully. Current open short interest is 171.5K shares with a 2.35 days-to-cover ratio. Daily short ratios have spiked as high as 24%, though recent data tracks closer to 4–5%. With 2.69M historical open short interest, the setup is primed for squeezes if catalysts break positively. Short positioning here is more an accelerant than a thesis, but it matters.

📊 Technicals compressing into breakout

I’m watching the charts tighten. On the daily, ALGS has coiled between $7.50 and $9.00. The 4H shows EMAs stacking with volatility bands narrowing, while the 30m chart highlights expansion candles pressing into $9. A breakout over $10 unlocks $13–$15, then $20. Beyond that, analyst PTs at $50+ are a clear probability-weighted roadmap.

🏦 ETF flows quietly backstop the story

“$ALGS is already inside major institutional baskets. Vanguard’s Total Stock Market ETF (VTI) holds ~$710K, VXF another ~$308K, and Schwab’s Small-Cap ETF $192K. Passive flows may look small on paper, but they provide a structural bid that anchors downside. Even when sentiment wavers, ALGS remains inside systematic flows that don’t panic-sell.”

👥 Insider alignment signals confidence

I’m confident management is aligning with shareholders. The August inducement grant of 42,300 shares at market price, vesting over four years, ties new hires directly to the company’s future success. This is how you retain the scientific talent needed to see a long pipeline through.

🌐 Macro backdrop supports rotation

I’m focused on the sector overlay. Biotech has lagged broader indices like $QQQ and $SPY in 2025, but rotations can be violent. With Fed rate cuts expected into September, risk appetite for high-beta, clinical-stage plays could expand rapidly. In that environment, $ALGS is structurally positioned to benefit from even modest risk-on flows.

🚀 Where fundamentals and positioning collide

I’m unequivocally optimistic. The market sees a cash-burning microcap with uneven income statements. I see a derisked HBV pipeline, a healthy cash runway, analyst conviction with 10x+ upside, insider alignment, and shorts vulnerable to repricing.

This isn’t just a trade; it’s a conviction thesis where science, capital, and positioning collide into one of the most asymmetric opportunities in biotech today.

Are you watching this as a misunderstood asymmetry, or do you think the market is right to heavily discount $ALGS until Phase 2 data matures?

📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀

Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀

@Tiger_comments @TigerPicks @TigerWire @TigerObserver @TigerStars @Daily_Discussion